Nintedanib: Patient-Friendly Guide (United Kingdom)

Nintedanib is a medicine used to help slow the progression of certain serious lung conditions. This guide explains what nintedanib is, how it works, how the body handles it (pharmacokinetics), how it is typically taken, key safety information, and practical tips to help you use it more comfortably. It also covers interactions with food, alcohol and medicines, plus frequently asked questions.

Important: This information is for general education. Always follow the specific instructions provided by your healthcare team and read the patient information leaflet (PIL) supplied with the medicine.

Basic product information

How nintedanib works (mechanism of action)

Nintedanib belongs to a class of medicines called tyrosine kinase inhibitors. It blocks multiple signalling pathways involved in fibrosis (the process that leads to scarring and thickening of lung tissue).

In particular, nintedanib inhibits signalling related to growth factor receptors such as:

• VEGFR (vascular endothelial growth factor receptors)
• FGFR (fibroblast growth factor receptors)
• PDGFR (platelet-derived growth factor receptors)

By reducing these profibrotic and pro-growth signals, nintedanib may help slow the decline in lung function and the progression of certain ILDs.

Typical uses in the UK

Nintedanib is used to treat selected progressive forms of interstitial lung disease and other specified ILDs, in line with current national and clinical guidance. The exact eligible condition depends on your diagnosis, disease severity, and the presence of progressive behaviour.

Your healthcare team will determine whether nintedanib is appropriate based on:

• Your specific ILD diagnosis
• Evidence of progression (for example, worsening lung function or symptoms)
• Clinical findings and test results (such as imaging and lung function tests)
• Other medical conditions and medicines you take

Note: Eligibility and prescribing practices may vary depending on NHS pathways and specialist decisions.

Pharmacokinetics (how the body handles it)

Understanding how nintedanib is absorbed and processed can help you use it more safely. The key points below are presented in patient-friendly terms.

Absorption

Nintedanib is absorbed after oral dosing, reaching peak blood levels at a few hours after taking a capsule. Absorption may be affected by food, so consistent timing and guidance about meals matter.

Distribution

Once absorbed, nintedanib circulates through the bloodstream and is distributed throughout the body. It is designed to target specific signalling pathways relevant to fibrosis.

Metabolism (breakdown)

Nintedanib is mainly metabolised by enzymes in the liver, particularly the CYP3A4 pathway. This is one reason it may interact with medicines that either increase or decrease CYP3A4 activity.

Elimination

The medicine is cleared from the body via both metabolic processes and elimination routes. The dosing frequency (typically twice daily in many regimens) is designed to maintain effective exposure.

Dosing: typical timing and how to take it

Dosing should always be individualised. Below are typical dosing patterns used in practice. Your prescription instructions and the medicine’s PIL should be followed exactly.

Common dosing schedule

• Typically twice daily (morning and evening), about 12 hours apart.

Consistency is important

Try to take your doses at approximately the same times each day. Setting reminders may help.

How to take the capsules

• Swallow capsules whole with water.
• Do not crush, chew, or open the capsules (unless your PIL specifically instructs otherwise).
• If you miss a dose, do not take a double dose to make up for it—ask your pharmacist or follow the PIL advice.

Timing relative to meals

Food can affect how much nintedanib your body absorbs. Many patients are advised to take nintedanib with food or to keep the approach consistent (for example, always with meals). Follow the exact instructions given for your product.

If you experience stomach upset or diarrhoea, your clinician may suggest timing changes or supportive treatments.

Food interactions (what to know)

Food may influence absorption and peak levels. In general:

• Take with meals if advised by your prescribing information or PIL.
• Avoid sudden routine changes in meal timing (for example, switching from evening-with-food to fasted dosing) unless your healthcare team approves it.
• If you have nausea, appetite changes, or diarrhoea, smaller, frequent meals may be easier to tolerate.

For the safest results, aim for consistent habits day-to-day and check the PIL for detailed guidance.

Alcohol and medicine interactions

Alcohol

Alcohol may increase the risk of irritation to the stomach, dehydration, or may affect liver function. Since nintedanib can have effects on liver enzymes, it is advisable to:

• Use alcohol cautiously, especially if you have liver enzyme changes or experience diarrhoea.
• Discuss safe limits with your clinician.

Interactions with other medicines

Because nintedanib is metabolised partly by CYP3A4, some medicines can raise or lower its levels. This can increase side effects or reduce effectiveness.

Examples of important interaction categories include:

• CYP3A4 inhibitors (may increase nintedanib exposure)
• CYP3A4 inducers (may decrease nintedanib exposure)
• Medicines affecting clotting (nintedanib may increase bleeding risk in some circumstances)
• Medicines that can affect the liver (additive liver stress may occur)
• P-glycoprotein (P-gp) related medicines (can influence absorption/transport)

Always provide your pharmacist and healthcare team with a full list of:

• All prescription medicines
• Over-the-counter medicines
• Herbal products and supplements
• Recent changes (including antibiotics or antifungals)

If you start a new medicine, confirm with a healthcare professional whether it may interact with nintedanib.

Indications (when nintedanib may be used)

In the UK, nintedanib is used for certain interstitial lung diseases (ILDs) that involve scarring and a risk of progression. Indications are defined by specific diagnostic criteria, disease behaviour (progressive or fibrosing), and clinical context.

Your treating team will confirm whether your condition matches the approved use for nintedanib. If you are unsure, ask:

• Which ILD subtype you have
• Whether your disease is considered progressive
• What outcome is expected (for example, slowing lung function decline)
• How long therapy is planned to continue

Safety profile: common and important side effects

Like all medicines, nintedanib can cause side effects. Many are manageable, but some require prompt medical attention. The sections below are not exhaustive—refer to the PIL and seek medical advice if you have concerns.

Common side effects

• Diarrhoea (very common). Often appears early and may respond to anti-diarrhoeal treatment.
• Nausea or vomiting
• Reduced appetite
• Abdominal pain or indigestion
• Fatigue
• Elevated liver enzymes detected on blood tests

Other possible effects

• Decreased weight (often related to appetite changes and gastrointestinal effects)
• Headache
• Rash or skin reactions
• High blood pressure (occasionally)
• Bleeding risk in certain situations

Seek urgent medical help if you notice

• Severe or persistent diarrhoea, especially with dizziness, fainting, or signs of dehydration
• Blood in vomit or black/tarry stools
• Severe abdominal pain or signs of serious infection
• Yellowing of the eyes/skin (jaundice) or very dark urine (possible liver issues)
• Shortness of breath worsening rapidly, chest pain, or sudden swelling

Monitoring (tests your clinicians may do)

Monitoring is an important part of safe use. Your team may arrange:

• Liver function tests (blood tests to monitor enzymes)
• Blood pressure checks
• Assessment of symptoms such as diarrhoea, appetite, and weight
• Review of your other medications and potential interactions

Practical use tips for patients

Many people find that small routines improve tolerability. The tips below are commonly helpful.

Manage diarrhoea early

• At the first sign of diarrhoea, contact your healthcare team promptly.
• Follow guidance on anti-diarrhoeal medicines if recommended (for example, loperamide-type regimens if appropriate for you).
• Drink fluids and consider oral rehydration solutions if you are losing fluids.
• Avoid dehydration, which can affect kidney function and overall well-being.
• Keep track of how many times you have diarrhoea in 24 hours to report accurately.

Protect your liver and report symptoms

• Attend scheduled blood tests for liver enzymes.
• Tell your clinician if you develop symptoms such as jaundice, severe fatigue, or persistent nausea.
• Avoid starting new liver-stressing medicines or supplements without advice.

Plan around appointments and travel

• Bring your medication with you (original packaging if possible).
• Keep spare capsules for missed doses due to travel or appointments.
• Plan meals and hydration to reduce stomach upset.

Keep a medication log

A simple log can help you and your healthcare team spot patterns:

• Date/time of each dose
• Meals timing
• Any side effects (severity and timing)
• Other medications taken that day

Alternative options

The best alternative depends entirely on your specific diagnosis and clinical situation. If nintedanib is not suitable, your healthcare team may consider other approaches, such as:

Other antifibrotic medicines

• Pirfenidone (for certain idiopathic pulmonary fibrosis and related indications, depending on eligibility)
• Other locally available antifibrotics as recommended by specialist ILD services

Supportive and disease-management options

• Oxygen therapy (if needed)
• Pulmonary rehabilitation and exercise programmes
• Vaccinations and symptom management (as appropriate)
• Treating reflux, infections, or breathlessness triggers

Your clinician may also review whether other underlying causes are present and whether additional treatments are appropriate.

Market and legal context in the UK

Nintedanib is an established medicine within specialist care for certain progressive or fibrosing interstitial lung diseases. In the UK, availability and use are shaped by:

• Regulatory approvals and product licensing
• National health guidance and specialist ILD pathways
• Funding decisions and prescribing policies across NHS services
• Monitoring requirements for safety

Because clinical eligibility and funding can change with new evidence and health technology assessments, it is important to rely on updated advice from your healthcare provider and local ILD team.

Recent guidance (how to stay up to date)

ILD management guidance can evolve as new trial results and real-world evidence emerge. For the most current recommendations, healthcare professionals may refer to:

• UK and international clinical guidelines for ILD (including progressive pulmonary fibrosis pathways)
• Specialist multidisciplinary team (MDT) decisions
• Updates to safety monitoring recommendations in the medicine’s current PIL

If you would like, you can ask your specialist team whether your condition is being assessed under the latest UK guidance.

Delivery and availability from a UK online pharmacy

Availability can depend on stock levels, manufacturer supply, and local regulations. Many online pharmacies in the UK offer delivery to UK addresses, often with tracking and delivery time estimates at checkout.

What to expect

• Ordering: You may be asked to confirm details to ensure the correct medicine strength and quantity.
• Dispatch: Orders are usually dispatched once verified and packaged.
• Delivery: Delivery times vary; tracked delivery may be available.
• Packaging: Medicines are shipped in secure packaging with clear labels.

Storage at home

• Store according to the instructions on the PIL or outer carton.
• Keep capsules in their original container to protect from moisture and maintain correct identification.
• Keep out of the sight and reach of children.

If you are delayed in receiving medication, contact the pharmacy for advice on what to do with upcoming doses.

FAQ about nintedanib

1) What is nintedanib used for?

Nintedanib is used to help slow the progression of certain interstitial lung diseases that involve scarring and a risk of worsening over time. Your specialist will confirm whether your diagnosis matches an approved indication.

2) How should I take it?

It is taken by mouth, usually twice daily at roughly the same times each day. Capsules should be swallowed whole with water. Follow the timing instructions from your PIL and healthcare team—food can affect absorption.

3) Can I take nintedanib with food?

Many patients are advised to take it with food or to keep dosing consistent with meals. The precise instruction depends on the product’s guidance. Check your PIL and follow the instruction given to you.

4) What side effects are most common?

Diarrhoea is the most common. Other gastrointestinal effects (nausea, stomach discomfort), reduced appetite, fatigue, and liver enzyme elevations may also occur.

5) What should I do if I get diarrhoea?

Contact your healthcare team promptly, especially if diarrhoea is frequent or persistent. Focus on hydration and follow advice on anti-diarrhoeal medicines if recommended. If you feel dizzy, faint, or cannot keep fluids down, seek urgent medical care.

6) Will nintedanib interact with other medicines?

Yes. Because nintedanib is metabolised in the liver (including via CYP3A4), some medicines can change its blood levels. Always tell your pharmacist or clinician about all medicines and supplements you use.

7) Can I drink alcohol while taking nintedanib?

Alcohol should be used cautiously. It may worsen gastrointestinal side effects and can affect liver function. Discuss safe intake with your healthcare team, particularly if you have liver enzyme changes.

8) Does nintedanib affect my liver?

It can. Liver function tests are commonly monitored during treatment. Report symptoms suggestive of liver problems (such as jaundice or dark urine).

9) What if I miss a dose?

Do not take an extra dose to catch up unless your PIL or healthcare team tells you to. If you are unsure, ask your pharmacist for guidance based on your dosing schedule.

10) Are there alternatives if nintedanib isn’t tolerated?

Depending on your diagnosis, other treatments may be considered, including alternative antifibrotic options and supportive care approaches. Your specialist can discuss benefits and risks of each option.

Key takeaways

• Nintedanib is an oral medicine used to help slow progression of certain fibrosing and progressive ILDs.
• It works by inhibiting multiple signalling pathways involved in fibrosis.
• Diarrhoea is the most common side effect—early management and hydration are important.
• Food and medicine interactions matter; aim for consistent meal timing and tell your team about all medicines you take.
• Liver monitoring is a key safety step during treatment.

If you have questions about suitability for your condition, side effects, or interactions, speak with your pharmacist or healthcare team. Your online pharmacy can also help you understand delivery options and what to do if you have missed doses or concerns about tolerability.